AstraZeneca's first half revenue in China was $3.515 billion, and they plan to expand their presence in the country.

On July 29, AstraZeneca announced its performance for the first half of 2025, achieving total revenue of $28.045 billion, a year-on-year increase of 11%. Product revenue was $27.963 billion, a year-on-year increase of 11%. By region, in the first half of the year, AstraZeneca's revenue in the US market was $11.97 billion, a year-on-year increase of 12%, while revenue in emerging markets was $7.697 billion, a year-on-year increase of 12%, with revenue in China reaching $3.515 billion, a year-on-year increase of 5%, accounting for more than 12% of global revenue. "We are optimistic about China's innovative potential and will continue to expand our research and development presence in China." AstraZeneca disclosed that in March, the company announced a $25 billion investment plan in China, including the establishment of the sixth global strategic research and development center in Beijing. Currently, AstraZeneca has established two out of its six global strategic research and development centers in China.